rs879254471
Variant summary
Our verdict is Pathogenic. The variant received 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_000527.5(LDLR):c.314-1G>A variant causes a splice acceptor, intron change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000527.5 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Publications
- hypercholesterolemia, familial, 1Inheritance: AD, SD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Laboratory for Molecular Medicine, ClinGen
- homozygous familial hypercholesterolemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LDLR | NM_000527.5 | c.314-1G>A | splice_acceptor_variant, intron_variant | Intron 3 of 17 | ENST00000558518.6 | NP_000518.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Hypercholesterolemia, familial, 1 Pathogenic:5
- -
This variant causes a G to A nucleotide substitution at the -1 position of intron 3 of the LDLR gene. Splice site prediction tools suggest that this variant may have a significant impact on RNA splicing. A functional RNA study using lymphocytes derived from a heterozygous carrier individual has shown that this variant causes abnormal splicing, leading to skipping of exon 4 (PMID: 19208450). Additionally, flow cytometry analysis of these carrier-derived lymphocytes has shown that this variant causes a significant reduction in residual LDLR activity (PMID: 19208450). This variant has been reported in more than 10 individuals affected with familial hypercholesterolemia (PMID: 9452078, 11810272, 20506408, 21382890, 30795984, 31048103, 36604244). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of LDLR function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
- -
- -
- -
Familial hypercholesterolemia Pathogenic:3
For these reasons, this variant has been classified as Pathogenic. This sequence change affects an acceptor splice site in intron 3 of the LDLR gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in a shortened protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with familial hypercholesterolemia (PMID: 9452078, 31048103). This variant is also known as S285L. ClinVar contains an entry for this variant (Variation ID: 251148). Studies have shown that disruption of this splice site results in skipping of exon 4, but is expected to preserve the integrity of the reading-frame (PMID: 19208450). This variant disrupts the p.Cys109 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9544745, 11313767, 22883975, 24956927). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. -
This variant causes a G to A nucleotide substitution at the -1 position of intron 3 of the LDLR gene. Splice site prediction tools suggest that this variant may have a significant impact on RNA splicing. A functional RNA study using lymphocytes derived from a heterozygous carrier individual has shown that this variant causes abnormal splicing, leading to skipping of exon 4 (PMID: 19208450). Additionally, flow cytometry analysis of these carrier-derived lymphocytes has shown that this variant causes a significant reduction in residual LDLR activity (PMID: 19208450). This variant has been reported in more than 10 individuals affected with familial hypercholesterolemia (PMID: 9452078, 11810272, 20506408, 21382890, 30795984, 31048103, 36604244). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of LDLR function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
Variant summary: LDLR c.314-1G>A alters a conserved nucleotide located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes the canonical 3' splice acceptor site. At least one publication reports experimental evidence that this variant affects mRNA splicing resulting in skipping of exon 4 (example, Holla_2009). The variant was absent in 249626 control chromosomes. c.314-1G>A has been reported in the literature in individuals affected with Familial Hypercholesterolemia (example, Lombardi_1998, Luirink_2019, Fouchier_2001). At least one publication reports experimental evidence evaluating an impact on protein function (example, Holla_2009). The most pronounced variant effect results in decrease in LDL-receptor activity (approximately 41% of wild type), decrease in LDL internalization (approximately 30% of wild type) and decrease in cell surface LDL-receptor levels (approximately 50% of wild type). Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
not provided Pathogenic:2
Not observed at significant frequency in large population cohorts (gnomAD); Canonical splice site variant expected to result in aberrant splicing and loss of adjacent in-frame exon; Published functional studies using flow cytometry in patient cells show abnormal splicing leading to skipping of exon 4 or retention of intron 3 (Holla et al., 2009); Deletions involving coding exons of this gene are a known mechanism of disease (HGMD); This variant is associated with the following publications: (PMID: 22294733, 25911074, 11810272, 20506408, 21382890, 22390909, 30795984, 31048103, 9452078, 19208450) -
- -
Cardiovascular phenotype Pathogenic:1
The c.314-1G>A pathogenic mutation, results from a G to A one nucleotide upstream from coding exon 4 of the LDLR gene. This alteration has been reported in familial hypercholestremia (FH) patients (Huijgen et al 2010; Hum Mut 31(6):752-60; Lombardi P et al. Hum Mutat, 1998;Suppl 1:S172-4; Luirink IK et al. Atherosclerosis, 2019 06;285:87-92). This alteration has also been shown to have an impact on protein function (Holla ØL et al. Mol Genet Metab, 2009 Apr;96:245-52). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at